74,737 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 74,737 shares of the medical device company’s stock, valued at approximately $5,812,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Heck Capital Advisors LLC bought a new position in DexCom during the 4th quarter worth $38,000. SBI Securities Co. Ltd. acquired a new stake in DexCom in the 4th quarter worth about $49,000. Finally, Midwest Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $54,000. 97.75% of the stock is owned by institutional investors.

DexCom Trading Up 3.2 %

Shares of DXCM stock opened at $70.69 on Monday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business’s fifty day moving average is $83.99 and its 200 day moving average is $76.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $27.62 billion, a PE ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,657 shares of company stock worth $8,019,422 in the last quarter. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DXCM shares. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.